Eric Daniels

Corporate Officer/Principal bei KIORA PHARMACEUTICALS, INC.

Vermögen: 42 288 $ am 30.04.2024

51 Jahre

Consumer Services

Health Technology

Commercial Services

Aktive Positionen von Eric Daniels

Unternehmen	Position	Beginn	Ende
KIORA PHARMACEUTICALS, INC.	Corporate Officer/Principal	21.10.2021	-
Okogen, Inc. Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA.	Direktor/Vorstandsmitglied	-	-
	Gründer	-	-
Bayon Therapeutics, Inc.	Direktor/Vorstandsmitglied	-	-
Bayon Therapeutics, Inc.	Gründer	-	-

Unternehmen	Position	Beginn	Ende
OccuRx Pty Ltd OccuRx Pty Ltd BiotechnologyHealth Technology OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia.	Vorstandsvorsitzender	-	-

University of California, Berkeley	Undergraduate Degree
David Geffen School of Medicine	Doctorate Degree
Anderson School of Management	Masters Business Admin

International

Vereinigte Staaten	7
Australien	2

Operativ

Director/Board Member	2
Founder	2
Corporate Officer/Principal	1

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
KIORA PHARMACEUTICALS, INC.	Health Technology

Private Unternehmen	3
Okogen, Inc. Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA.	Commercial Services
OccuRx Pty Ltd OccuRx Pty Ltd BiotechnologyHealth Technology OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia.	Health Technology
Bayon Therapeutics, Inc.